The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study
Hideaki Okumichi,1 Yoshiaki Kiuchi,1 Tetsuya Baba,2 Takashi Kanamoto,3 Tomoko Naito,4,5 Shunsuke Nakakura,6 Hitoshi Tabuchi,6 Hiroki Nii,7 Chie Sueoka,7 Yosuke Sugimoto1,8 1Department of Ophthalmology and Visual Science, Graduate School of Biomedical & Health Sciences, Hiroshima University,...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9c12189507f54285993c32dd6720882d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9c12189507f54285993c32dd6720882d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9c12189507f54285993c32dd6720882d2021-12-02T00:52:16ZThe signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study1177-5483https://doaj.org/article/9c12189507f54285993c32dd6720882d2017-06-01T00:00:00Zhttps://www.dovepress.com/the-signs-of-ocular-surface-disorders-after-switching-from-latanoprost-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Hideaki Okumichi,1 Yoshiaki Kiuchi,1 Tetsuya Baba,2 Takashi Kanamoto,3 Tomoko Naito,4,5 Shunsuke Nakakura,6 Hitoshi Tabuchi,6 Hiroki Nii,7 Chie Sueoka,7 Yosuke Sugimoto1,8 1Department of Ophthalmology and Visual Science, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan; 2Shirai Eye Hospital, Mitoyo, Japan; 3Department of Ophthalmology, Hiroshima Memorial Hospital, Hiroshima, Japan; 4Department of Ophthalmology, Okayama University Graduate School of Medicine, Okayama, Japan; 5Department of Ophthalmology, Konko Hospital, Asakuchi, Japan; 6Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan; 7Department of Ophthalmology, Hiroshima General Hospital, Hiroshima, Japan; 8Department of Ophthalmology, Hiroshima Prefectural Hospital, Hiroshima, Japan Purpose: To evaluate the ocular-surface safety of a 0.001% benzalkonium chloride-containing tafluprost/timolol fixed combination (TTFC) in patients with primary open-angle glaucoma (POAG) or ocular hypertension who have inadequate intraocular pressure (IOP) control with latanoprost monotherapy.Methods: This study is a multicenter, prospective, single-arm, open-label clinical study. Patients with POAG or ocular hypertension who have inadequate IOP control with latanoprost monotherapy were considered eligible. After providing informed consent, patients continued latanoprost monotherapy for 12 weeks, followed by a switch to TTFC. We evaluated the extent of ocular-surface damage using superficial punctate keratopathy (SPK) score, tear breakup time (TBUT), hyperemia score, IOP, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate at 0, 4, and 12 weeks after switching.Results: A total of 68 patients were enrolled, of whom, 64 patients were included in the final analysis. No significant changes in SPK score, TBUT, or hyperemia score were observed at 4 and 12 weeks compared with week 0. IOP decreased significantly at 4 (13.9±2.5 mmHg) and 12 (14.1±2.5 mmHg) weeks, relative to week 0 (15.3±2.7 mmHg). No significant changes in either SBP or DBP were observed during the study, although patients’ mean heart rate decreased significantly after switching to TTFC. Adverse drug reactions to TTFC occurred in seven patients including two incidences of asthma and one of arrhythmia, and no events were serious.Conclusion: The ocular-surface safety of TTFC is not significantly different to that of latanoprost. Furthermore, switching from latanoprost to TTFC in patients with insufficient IOP control has additive IOP-lowering effects. TTFC is an effective approach for patients receiving latanoprost monotherapy who require more intensive IOP reduction. Keywords: tafluprost/timolol fixed combination, latanoprost, glaucoma, ocular-surface safety, intraocular pressureOkumichi HKiuchi YBaba TKanamoto TNaito TNakakura STabuchi HNii HSueoka CSugimoto YDove Medical Pressarticletafluprost/timolol fixed combinationlatanoprostglaucomaocular-surface safetyintraocular pressureOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 1175-1181 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
tafluprost/timolol fixed combination latanoprost glaucoma ocular-surface safety intraocular pressure Ophthalmology RE1-994 |
| spellingShingle |
tafluprost/timolol fixed combination latanoprost glaucoma ocular-surface safety intraocular pressure Ophthalmology RE1-994 Okumichi H Kiuchi Y Baba T Kanamoto T Naito T Nakakura S Tabuchi H Nii H Sueoka C Sugimoto Y The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study |
| description |
Hideaki Okumichi,1 Yoshiaki Kiuchi,1 Tetsuya Baba,2 Takashi Kanamoto,3 Tomoko Naito,4,5 Shunsuke Nakakura,6 Hitoshi Tabuchi,6 Hiroki Nii,7 Chie Sueoka,7 Yosuke Sugimoto1,8 1Department of Ophthalmology and Visual Science, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan; 2Shirai Eye Hospital, Mitoyo, Japan; 3Department of Ophthalmology, Hiroshima Memorial Hospital, Hiroshima, Japan; 4Department of Ophthalmology, Okayama University Graduate School of Medicine, Okayama, Japan; 5Department of Ophthalmology, Konko Hospital, Asakuchi, Japan; 6Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan; 7Department of Ophthalmology, Hiroshima General Hospital, Hiroshima, Japan; 8Department of Ophthalmology, Hiroshima Prefectural Hospital, Hiroshima, Japan Purpose: To evaluate the ocular-surface safety of a 0.001% benzalkonium chloride-containing tafluprost/timolol fixed combination (TTFC) in patients with primary open-angle glaucoma (POAG) or ocular hypertension who have inadequate intraocular pressure (IOP) control with latanoprost monotherapy.Methods: This study is a multicenter, prospective, single-arm, open-label clinical study. Patients with POAG or ocular hypertension who have inadequate IOP control with latanoprost monotherapy were considered eligible. After providing informed consent, patients continued latanoprost monotherapy for 12 weeks, followed by a switch to TTFC. We evaluated the extent of ocular-surface damage using superficial punctate keratopathy (SPK) score, tear breakup time (TBUT), hyperemia score, IOP, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate at 0, 4, and 12 weeks after switching.Results: A total of 68 patients were enrolled, of whom, 64 patients were included in the final analysis. No significant changes in SPK score, TBUT, or hyperemia score were observed at 4 and 12 weeks compared with week 0. IOP decreased significantly at 4 (13.9±2.5 mmHg) and 12 (14.1±2.5 mmHg) weeks, relative to week 0 (15.3±2.7 mmHg). No significant changes in either SBP or DBP were observed during the study, although patients’ mean heart rate decreased significantly after switching to TTFC. Adverse drug reactions to TTFC occurred in seven patients including two incidences of asthma and one of arrhythmia, and no events were serious.Conclusion: The ocular-surface safety of TTFC is not significantly different to that of latanoprost. Furthermore, switching from latanoprost to TTFC in patients with insufficient IOP control has additive IOP-lowering effects. TTFC is an effective approach for patients receiving latanoprost monotherapy who require more intensive IOP reduction. Keywords: tafluprost/timolol fixed combination, latanoprost, glaucoma, ocular-surface safety, intraocular pressure |
| format |
article |
| author |
Okumichi H Kiuchi Y Baba T Kanamoto T Naito T Nakakura S Tabuchi H Nii H Sueoka C Sugimoto Y |
| author_facet |
Okumichi H Kiuchi Y Baba T Kanamoto T Naito T Nakakura S Tabuchi H Nii H Sueoka C Sugimoto Y |
| author_sort |
Okumichi H |
| title |
The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study |
| title_short |
The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study |
| title_full |
The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study |
| title_fullStr |
The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study |
| title_full_unstemmed |
The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study |
| title_sort |
signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/9c12189507f54285993c32dd6720882d |
| work_keys_str_mv |
AT okumichih thesignsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT kiuchiy thesignsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT babat thesignsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT kanamotot thesignsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT naitot thesignsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT nakakuras thesignsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT tabuchih thesignsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT niih thesignsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT sueokac thesignsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT sugimotoy thesignsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT okumichih signsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT kiuchiy signsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT babat signsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT kanamotot signsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT naitot signsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT nakakuras signsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT tabuchih signsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT niih signsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT sueokac signsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy AT sugimotoy signsofocularsurfacedisordersafterswitchingfromlatanoprosttotafluprosttimololfixedcombinationaprospectivestudy |
| _version_ |
1718403454517379072 |